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increased frequencies of dizziness, headache, constipation, dysgeusia, decreased appetite 
and grade 3/4 neutropenia in Asian patients and edema and fatigue in non-Asian 
patients. The relationship between crizotinib exposure and efficacy warrants further 
investigation.
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O-028: CLINICAL ACTIVITY OF CRIZOTINIB IN PATIENTS WITH 
ADVANCED NON-SMALL CELL LUNG CANCER HARBORING THE 
ROS1 GENE REARRANGEMENT
Sai-hong I. Ou1, Y-j Bang2, D R. Camidge3, J A. Engelman4, J W. Clark4, L Tye5, Keith 
Wilner5, P Stephenson6, D H. Chung2, M Varella-Garcia3, A J. Iafrate4, A T. Shaw4  
1Medicine-Hematology/Oncology, Chao Family Comprehensive Cancer Center/
University Of California Irvine, Orange/CA/UNITED STATES OF AMERICA, 2Seoul 
National University Hospital, Seoul/KOREA, 3University Of Colorado Cancer Center, 
Aurora/CO/UNITED STATES OF AMERICA, 4Massachusetts General Hospital Cancer 
Center, Boston/MA/UNITED STATES OF AMERICA, 5Pfizer Oncology, La Jolla/CA/
UNITED STATES OF AMERICA, 6Rho, Inc., Chapel Hill/NC/UNITED STATES OF 
AMERICA
Background: Chromosomal rearrangements in the receptor tyrosine kinase (RTK) 
gene ROS1 define a new molecular subset of non-small cell lung cancer (NSCLC). 
Crizotinib, a small-molecule inhibitor of ALK and MET, inhibits ROS1 kinase activity 
in cell lines. We examined the efficacy and safety of crizotinib in patients with advanced, 
ROS1-rearranged NSCLC. Methods: Patients with advanced NSCLC harboring ROS1 
rearrangements, as determined using a break-apart FISH assay, were recruited into 
an expansion cohort of an early phase I study of crizotinib. Patients were treated with 
crizotinib at the standard oral dose of 250 mg twice daily. The objective response rate 
(ORR) was determined based on Response Evaluation Criteria in Solid Tumors version 
1.0. The disease control rate (DCR: percent stable disease [SD] + partial response [PR] 
+ complete response [CR]) was evaluated at weeks 8 and 16. Results: Twenty patients 
with ROS1-positive NSCLC have enrolled in the trial to date. At the time of data cut-off 
(April 19, 2012), 15 patients had received crizotinib and 14 were evaluable for response. 
The median age was 54 years (range, 31–72). Fourteen patients were never-smokers. All 
had NSCLC with an adenocarcinoma histology that was confirmed negative for ALK 
rearrangement. The median number of prior treatments was 1 (range, 0–6). The first 
patient with ROS1-positive disease received crizotinib on October 19, 2010. At data 
cut-off, among response-evaluable patients, the ORR was 57% (8/14; 95% CI, 28.9–82.3), 
with 7 PRs and 1 CR. Four patients had SD, one of which was unconfirmed as a PR. The 
DCR at 8 weeks was 79% (11/14). Median duration of treatment was 25.7 weeks (range, 
0.1+ to 65.3+), and 12 of the 15 patients who had received crizotinib at data cut-off 
were continuing on study. The pharmacokinetics, antitumor activity, and safety profile 
of crizotinib in this group of patients were similar to those observed in patients with 
ALK-positive NSCLC. Updated efficacy results will be presented, as enrollment is active 
and ongoing. Conclusion: Crizotinib is associated with clinically significant antitumor 
activity in patients with ROS1-positive NSCLC. Similar to ALK, ROS1 rearrangement 
defines another unique molecular subset of NSCLC for which crizotinib therapy may be 
highly effective. Importantly, this study represents the first clinical investigation of ROS1 
gene rearrangements as a therapeutic target in cancer.
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O-029: PARACRINE RECEPTOR LIGANDS ACTIVATE BYPASS 
TRACTS AND CAUSE ALK INHIBITOR RESISTANCE IN EML4-ALK 
LUNG CANCER CELLS
Tadaaki Yamada1, Shinji Takeuchi1, Junya Nakade1, Takayuki Nakagawa1, Shigeki Nanjo1, 
Hiromichi Ebi1, Takahiro Nakamura2, Kunio Matsumoto2, Manabu Soda3, Hiroyuki 
Mano3, Seiji Yano1  
1Division Of Medical Oncology, Cancer Research Institute, Kanazawa University, 
Kanazawa/JAPAN, 2Division Of Tumor Dynamics And Regulation, Cancer Research 
Institute, Kanazawa University/JAPAN, 3Division Of Functional Genomics, Jichi 
Medical University/JAPAN
Background: Cancer cell microenvironments, including host cells, can critically affect 
cancer cell behaviors, including drug sensitivity. We recently reported that hepatocyte 
growth factor (HGF), the ligand of a tyrosine kinase receptor Met, can be produced not 
only by cancer cells but also host fibroblasts, activates Met and the downstream PI3K/
Akt pathway and triggers resistance to EGFR inhibitors in EGFR mutant lung cancer 
cells. Crizotinib, a dual inhibitor of ALK and Met, shows dramatic effects against EML4-
ALK lung cancer cells, but these cells can acquire resistance by several mechanisms, 
including ALK amplification and gatekeeper mutation. Although selective ALK 
inhibitors can overcome crizotinib resistance due to these mechanisms, these cells may 
become resistant to these inhibitors. Here, we determined whether microenvironmental 
factors trigger ALK inhibitor resistance in EML4-ALK lung cancer cells. Methods: 
We tested the effects of ligands produced by endothelial cells and fibroblasts, and the 
cells themselves, on the susceptibility of EML4-ALK lung cancer cell lines to crizotinib 
and TAE684, a selective ALK inhibitor active against cells with ALK amplification and 
gatekeeper mutations, both in vitro and in vivo. Results: EML4-ALK lung cancer cells 
were highly sensitive to ALK inhibitors. EGF receptor (EGFR) ligands, such as EGF, 
TGF-α, and HB-EGF, activated EGFR and triggered resistance to crizotinib and TAE684 
by transducing bypass survival signaling through Erk1/2 and Akt. Hepatocyte growth 
factor (HGF) activated Met/Gab1 and triggered resistance to TAE684, but not crizotinib, 
which inhibits Met. Endothelial cells and fibroblasts, which produce the EGFR ligands 
and HGF, respectively, decreased the sensitivity of EML4-ALK lung cancer cells to 
crizotinib and TAE684, respectively. EGFR-TKIs resensitized these cells to crizotinib 
and Met-TKI to TAE684 even in the presence of EGFR ligands and HGF, respectively. 
Conclusion: Our findings suggest that paracrine receptor activation by ligands from the 
microenvironment may trigger resistance to ALK inhibitors in EML4-ALK lung cancer 
cells, and provide a rationale for targeting receptor ligands in the microenvironment for 
more successful treatment with ALK inhibitors. These observation further raise clinical 
questions which classes ALK inhibitors are more beneficial for EML4-ALK lung cancer 
patients.
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O-030: EVALUATION OF PTPRF EXPRESSION AS A POTENTIAL 
PROGNOSTIC/PREDICTIVE BIOMARKER FOR ERLOTINIB-
TREATED NON-SMALL CELL LUNG CANCER (NSCLC)
Denis Soulières1, Barbara Klughammer2, Walter Bordogna2, Paul Delmar2 
1Centre Hospitalier de l’Université de Montréal, Montréal/CANADA, 2F. Hoffmann-La 
Roche, Ltd., Basel/SWITZERLAND
Background: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine-kinase 
inhibitor that has demonstrated efficacy in the maintenance and second-/third-line 
treatment of unselected NSCLC patients. Erlotinib has also demonstrated efficacy in the 
first-line treatment of patients with EGFR mutation-positive NSCLC. The establishment of 
predictive biomarkers, particularly for wild-type disease, could potentially help patients, 
physicians and payers optimize erlotinib treatment decisions. PTPRF (protein receptor-
type tyrosine phosphatase F), is involved in EGFR dephosphorylation, and we aimed to 
establish whether it has a role as a predictive/prognostic biomarker for erlotinib treatment 
of NSCLC. Methods: MERIT was a single-arm, phase II clinical trial (1) in which all 
patients had biopsy performed by bronchoscopy before starting erlotinib treatment 
(150mg/day orally). Biopsies were snap frozen, and laser capture microdissection of tumor 
cells was used to isolate and amplify mRNA. Affymetrix HGU-133A microarrays were 
used to analyse gene expression profiles. Exploratory statistical methods identified several 
gene candidates by comparing benefitting and non-benefitting patients. Gene candidates 
were analyzed and confirmed in formalin-fixed paraffin embedded (FFPE) tissue using 
qRT-PCR. To examine the marker of interest (PTPRF) further, FFPE tissue from the 
independent randomized phase III SATURN trial (2) was also analyzed using qRT-PCR 
and assessed for prognostic/predictive markers. High (>median) and low (<median) gene 
expression was assessed for correlations with progression-free survival (PFS) and overall 
survival (OS). Results: PTPRF expression was greater in patients who benefited from 
erlotinib treatment in MERIT, compared with those who did not benefit. SATURN also 
suggested a predictive role for PTPRF; a larger treatment effect was observed in patients 
with high levels of PTPRF (Table). Multivariate analysis of these data will be presented. 
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O-031: FIBROBLAST GROWTH FACTOR RECEPTOR 1 GENE 
AMPLIFICATION IS ASSOCIATED WITH POOR SURVIVAL AND 
CIGARETTE SMOKING DOSAGE IN RESECTED SQUAMOUS CELL 
LUNG CANCER PATIENTS
Byoung Chul Cho  
Division Of Medical Oncology, Yonsei Cancer Center, Seoul/KOREA
Background: Fibroblast growth factor receptor 1 (FGFR1) is one of the most commonly 
amplified genes in human cancer. FGFR1 plays crucial roles in cancer development, 
and are targets for dysregulation by amplification, point mutations, or translocation. 
Amplification or activation of FGFR1 has been reported in oral squamous carcinoma, 
esophageal squamous cell carcinomas, ovarian cancer, bladder cancer, prostate cancer, 
rhabodomyosarcoma, and lung cancer. This study was performed to investigate 
the frequency and the prognostic role of fibroblast growth factor receptor 1 (FGFR1) 
amplification in surgically resected lung squamous cell cancer (SqCC) patients and the 
association between smoking and FGFR1 amplification. Methods: Gene copy number of 
FGFR1 was investigated in microarrayed tumors from 262 SqCC patients with available 
tumor tissue as well as smoking and survival data (median follow-up 54.3 months). Gene 
copy number was evaluated by fluorescent in situ hybridization (FISH), and a FGFR1 
amplified tumor (FGFR1 amp+) was defined as a tumor with nine or more copies of FGFR1 
based on FISH analysis.  Results: Among 262 cases, the frequency of FGFR1 amp+ was 
13.0%. Patients with FGFR1 amp+ had significantly shorter disease-free survival (DFS) 
(26.9 vs. 94.6 months, P < 0.0001) as well as shorter overall survival (OS) (51.2 vs. 115.0 
months, P = 0.002) than those without FGFR1 amp+. Multivariate modeling confirmed 
that patients with FGFR1 amp+ had a significantly greater risk of recurrence and death 
than those without FGFR1 amp+ after adjusting for sex, smoking, pathologic stage, and 
adjuvant chemotherapy (AHR 2.24, 95% CI 1.45 -3.45, P < 0.001, DFS; AHR 1.82, 95% CI 
1.15-2.89, P = 0.01, OS). In FGFR1 amp+ group, the patients treated with adjuvant therapy 
showed the longer DFS and OS than those without adjuvant chemotherapy (12.7 vs. 40.8 
months in adjuvant chemotherapy, P < 0.0001 in DFS; 36.2 vs. 59.4 months in adjuvant 
chemotherapy, P = 0.004 in OS). FGFR1 amp- group patients did not benefit from adjuvant 
chemotherapy. The frequency of FGFR1 amp+ was significantly higher in current smokers 
than former and never smokers (28.9 vs. 2.5 vs. 0%, Ptrend < 0.0001). In terms of smoking 
dosage, the incidences of FGFR1 amp+ were 19.2% (15/78) in patients with 45 packs-years or 
more, 15.7% (14/89) in patients with 30-44 packs-years, 10.2% (4/39) in patients with 20-29 
packs-years, 5.2%(1/19) in patients with 10-19 packs-years, and 0% (0/37) in never smokers. 
As the smoking dosage (packs-years) increased, so did the incidence of FGFR1 amp+ (Ptrend 
= 0.002). Conclusion: FGFR1 amplification is an independent negative prognostic factor 
in surgically resected SqCC and is associated with cigarette smoking in a dose-dependent 
manner. FGFR1 amplification is a relevant therapeutic target in Asian lung SqCC patients.
Keywords: Fibroblast growth factor receptor, Non-small-cell lung cancer, Squamous 
Cell carcinoma, Predictive biomarker
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O-032: EML4-ALK REARRANGEMENT PREDICTED SIMILAR CHE-
MOTHERAPY RESPONSE COMPARED TO EGFR MUTANT, KRAS 
MUTANT AND TRIPLE NEGATIVE PATIENTS WITH ADVANCED 
NON-SMALL-CELL LUNG CANCER
Zhu Zeng1, Xu-chao Zhang2, Fei-yu Niu2, Zhi Xie2, Yi-long Wu2  
1Lung Cancer, Guangdong Lung Cancer Institute, Guangzhou/CHINA, 21. Guangdong 
Lung Cancer Institute, Guangdong General Hospital And Guangdong Academy Of 
Medical Sciences, Guangzhou, Guangzhou/CHINA
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Background: Echinoderm microtubule associated protein line 4-anaplastic lymphoma 
kinase (EML4-ALK) was identified as a novel subgroup of non-small-cell lung cancer 
(NSCLC). To assess whether the efficacy of chemotherapy in ALK-positive patients 
differs from that in ALK-negative subgroups, we did this retrospective study comparing 
progress free survival (PFS) and response rate (RR) in subgroups. Methods: Consecutive 
advanced inpatients tested EML4-ALK fusion, epidermal growth factor receptor (EGFR) 
mutation, and KRAS mutation were enrolled in this study. EML4-ALK was tested by 
rapid amplification of cDNA ends (RACE)-coupled PCR and sequencing and fluorescent 
in situ hybridization (FISH). Demographic and clinicopathological features, genotypes, 
and efficacy of therapy data were analyzed. Results: 264 cases of stage IV NSCLC were 
genotyped into four groups: 113 EGFR mutation (42.8%), 40 EML4-ALK fusion (15.2%), 
12 KRAS mutation (4.5%) and 99 triple gene wild type (WT) (37.5%). According to a 
total of 158 patients (EML4-ALK n=33, EGFR n=43, KRAS n=10, Triple-negative n=72) 
who used chemotherapy first-line treatment, there were not statistical differences of 
both PFS (P=0.857) and RR (P=0.341) among the genotyped four groups. In the 2nd line 
chemotherapy setting, EML4-ALK cohort (n=10) still showed similar efficacies comparing 
with EGFR mutant (n= 17), KRAS mutant (n=1) and triple-negative (WT, n=22) cohorts in 
terms of PFS (P=0.177) and RR (P=0.585). Different chemotherapy regiments, including 
pemetrexed, showed no statistical difference among these groups in both 1st and 2nd lines 
of therapy. In the EML4-ALK cohort, variants 1 (V1) was the most common EML4-ALK 
variant (37.5%), and associated with male gender (P=0.004). Comparing V1 and non-V1 
cohorts, there were still no differences in PFS and RR. Conclusion: EML4-ALK fusion 
may not be a predictive factor for chemotherapy, regardless of specific chemo-regimens, in 
advanced lung cancer patients.
Keywords: EML4-ALK, EGFR, LUNG CANCER, chemotherapy
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O-033: MECHANISM OF DIFFERENCE OF IN VITRO PEME-
TREXED SENSITIVITY BY HISTOLOGICAL TYPE IN NON-SMALL 
CELL LUNG CANCER
Tsukihisa Yoshida1, Tatsuro Okamoto1, Hirokazu Kitahara1, Shinichiro Shimamatsu1, 
Mikihiro Kohno1, Kenichi Suda1, Mitsuhiro Takenoyama2, Tokujiro Yano3, Yoshihiko 
Maehara1  
1Department Of Surgery And Science, Graduate School Of Medical Sciences, Kyushu 
Uuniversity, Fukuoka/JAPAN, 2Thoracic Oncology, Kyushu Cancer Center, Fukuoka/
JAPAN, 3Clinical Research Institute, National Beppu Medical Center, Beppu/JAPAN
Background: Pemetrexed (Alimta®, ALM) is a new multitarget antifolate metabolite 
anticancer drug. Non-small cell lung cancer is now treated with selective chemotherapy 
based on its classification as either non-squamous cell carcinoma or squamous cell 
carcinoma. This study was designed to investigate the relationship between in vitro 
chemosensitivity to ALM and both clinicopathological factors and the expressions of 
ALM-related enzymes and carrier molecule in non-small cell lung cancer. Methods: 
Seventy non-small cell lung cancer samples (56 adenocarcinoma and 14 squamous cell 
carcinoma) were used. Chemosensitivity was assessed by the succinate dehydrogenase 
inhibition (SDI) test for three antimetabolic anticancer drugs, including ALM, 
5-fluorouracil, gemcitabine. Samples showing more than the median of the succinate 
dehydrogenase (SD) activity, which reflects the cell viability, were defined as ‘Resistant’ 
and samples showing less than the median were defined as ‘Sensitive’. The mRNA 
expression levels of target enzymes of ALM (thymidylate synthase (TS), dihydrofolate 
reductase and glycinamide ribonucleotide formyltransferase), metabolic enzymes of 
ALM (γ-glutamyl hydrase (GGH) and folypolyglutamate synthase) and reduce folate 
carrier (RFC) were measured by reverse transcriptase polymerase chain reaction analysis 
to examine the influence on chemosensitivity to ALM. Results: Of 3 antimetabolic 
drugs, only ALM showed significant difference of chemosensitivity according to the 
histological type. Squamous cell carcinoma samples were more resistant to ALM than 
adenocarcinoma samples. In adenocarcinoma, no significant relationship between 
chemosensitivity to ALM and clinicopathological factors was observed. Squamous cell 
carcinoma samples showed higher expression of TS and lower expression of RFC than 
adenocarcinoma samples. In adenocarcinoma, only GGH was inversely correlated with 
chemosensitivity to ALM. Conclusion: The present study suggested that, in squamous 
cell carcinoma, the expressions of TS and RFC were associated with the chemosensitivity 
to ALM. In adenocarcinoma, the expression of GGH was associated with the 
chemosensitivity to ALM.
Keywords: sensitivity, Pemetrexed, Alimta, in vitro
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O-034: PHASE II STUDY OF ORAL S-1 AND CARBOPLATIN PLUS 
BEVACIZUMAB WITH MAINTENANCE S-1 AND BEVACIZUMAB 
AS FIRST-LINE THERAPY FOR ADVANCED NON-SQUAMOUS 
NON-SMALL-CELL LUNG CANCER 
Isamu Okamoto1, Yoshiko Urata2, Yoshihiro Hattori2, Keiko Okuno2, Temiko Shimada2, 
Masayuki Takeda2, Takayasu Kurata1, Masaki Miyazaki1, Hiroyasu Kaneda1, Masaaki 
Terashima1, Kaoru Tanaka1, Satoshi Morita3, Kazuhiko Nakagawa1, Shunichi Negoro2, 
Miyako Satouchi2  
1Department Of Medical Oncology, Kinki University Faculty Of Medicine, Osaka-
sayama/JAPAN, 2Department Of Thoracic Oncology, Hyogo Cancer Center, Akashi/
JAPAN, 3Department Of Biostatistics And Epidemiology, Graduate School Of Medicine, 
Yokohama City University, Yokohama/JAPAN
Background: S-1 (TS-1; Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) is an oral 
fluoropyrimidine anticancer agent combining tegafur as the effector drug with 
two modulators, gimeracil and oteracil potassium, in a molar ratio of 1:0.4:1. Our 
previous phase III trial, known as the “LETS” (Lung cancer Evaluation of TS-1) study, 
demonstrated the noninferiority of carboplatin/S-1 compared with carboplatin/
paclitaxel in terms of overall survival in chemo-naïve patients with advanced NSCLC 
(JCO vol28, 2010). In the present study, we have evaluated the efficacy and safety of 
new combination of S-1 and carboplatin plus bevasizumab followed by continuation 
maintenance of S-1 and bevacizumab in chemo-naïve patients with advanced non-
squamous NSCLC. Methods: Patients received carboplatin AUC 5 and bevacizumab 15 
mg/kg on day 1 plus oral S-1 (40 mg/m2 b.i.d. ) on days 1 to 14. Treatment is repeated 
every 21 days up to 6 cycles. For the patients with response or stable disease, S-1 
combined with bevacizumab are continued every 21 days until disease progression or 
toxicity. Primary endpoint of this study was overall response rate. Results: Between 
April 2010 to October 2011, 48 patients were enrolled. Median age was 65 years 
(range　35-77), male/female=33/15, PS 0/1=15/33, Adeno/Non-adeno=42/6. Thirty-five 
patients (73%) completed more than four treatment cycles and twenty-nine patients 
(60%) shifted to maintenance therapy. The median number of treatment cycles of 
maintenance therapy with S-1 plus bevacizumab was 4 (range, one to 13). Grade 3/4 
toxicities included: neutropenia (25%/6.3%), anemia (4.2%/6.3%), thrombocytopenia 
(10.4%/6.3%) and hypertension (8.3%/0%). No treatment related death was occurred. 
Among the 48 assessable for response, the objective response rate was 54 % (95% CI, 
39% to 67%) with a median progression free survival of 6.03 months (95% CI: 4.31-8.12). 
Conclusion: Treatment with S-1 and carboplatin plus bevacizumab with maintenance 
S-1 and bevacizumab in patients with advanced non-squamous NSCLC is feasible with 
an acceptable toxicity profile. The encouraging activity justifies further development of 
this new regimen.
Keywords: S-1, maintenance, Bevacizumab, non-squamous non-small-cell lung cancer
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O-035: INTERCALATED ERLOTINIB WITH GEMCITABINE/PLATI-
NUM IN THE FIRST-LINE TREATMENT OF CHINESE PATIENTS 
WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): 
SUBANALYSIS FROM THE FASTACT-2 STUDY
Yi-long Wu1, Meilin Liao2, Yunzhong Zhu3, Caicun Zhou4, Yan Sun5, Hongming Pan6, Jie 
Wang7, Xiaoping Qian8, Tony Mok9, Matt Truman10, Li Zhang11  
1Guangdong General Hospital & Guangdon Academy Of Medical Sciences, Guangdong 
Lung Cancer Institute, Guangzhou/CHINA, 2Shanghai Lung Tumor Clinical Medical 
Center, Shanghai/CHINA, 3Beijing Chest Hospital, Beijing/CHINA, 4Department 
Of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School Of 
Medicine, Shanghai/CHINA, 5Cancer Hospital/Institute, Chinese Academy Of Medical 
Science And Peking Union Medical College, Beijing/CHINA, 6Sir Run Run Shaw 
Hospital, Hangzhou/CHINA, 7Beijing Cancer Hospital, Beijing/CHINA, 8Nanjing Gulou 
Hospital, Nanjing/CHINA, 9Prince Of Wales Hospital, The Chinese University Of Hong 
Kong, Shatin/HONG KONG, 10Roche Products Pty Limited, Sydney/NSW/AUSTRALIA, 
11Cancer Center Of Sun Yat-Sen University, Guangzhou/CHINA
Background: FASTACT-2, a randomized, phase 3 study of intercalated erlotinib with 
gemcitabine/platinum in first-line advanced NSCLC, found that the intercalated regimen 
significantly prolonged progression-free survival (PFS) versus chemotherapy alone: HR 
0.57 (95% CI 0.46–0.70); p<0.0001; median 7.6 versus 6.0 months, respectively (Mok et al. 
ASCO 2012). FASTACT-2 enrolled patients across seven countries in East/South-East 
Asia: China, Hong Kong, Indonesia, Korea, the Philippines, Taiwan and Thailand. This 
subanalysis specifically examines the outcomes of patients recruited in China. Methods: 
Asian patients with stage IIIB/IV NSCLC and ECOG PS 0/1 who had received no prior 
treatment were randomized (1:1) to receive up to six cycles of gemcitabine (1,250 mg/
m2 on days 1 and 8) plus platinum (carboplatin 5×AUC or cisplatin 75 mg/m2 on day 1) 
every four weeks, with either intercalated erlotinib (150 mg/day on d15–28) or placebo. 
Those without disease progression after six cycles received maintenance erlotinib or 
placebo until progression, unacceptable toxicity or death. Patients were stratified by 
histology, smoking status, disease stage and chemotherapy regimen. PFS was the 
primary endpoint; other endpoints included overall response rate (ORR) and safety. 
Results: A total of 151 patients from China (out of a total study population of 451) were 
randomized to receive erlotinib (n=72) or placebo (n=79). Baseline demographics for the 
Chinese subpopulation were similar to those of the overall population and were well 
balanced across treatment arms. PFS was significantly prolonged with erlotinib versus 
placebo in the Chinese subpopulation: HR 0.57 (95% CI 0.39–0.82); log-rank p=0.0021; 
median 7.5 versus 6.5 months, respectively (Figure). This was confirmed by the 
independent review committee (IRC) analysis of PFS in this subpopulation: HR 0.56 
(95% CI 0.37–0.83); log-rank p=0.0038; median 11.0 versus 7.3 months, respectively. 
ORR was also significantly improved with erlotinib versus placebo for Chinese patients: 
43.1% versus 19.0%; p=0.0091. Adverse events were similar across both treatment arms in 
the Chinese subpopulation, with the exception of a higher incidence of skin rash in the 
erlotinib arm versus placebo (58% versus 33%). Updated data with a June 2012 cut-off 
will be presented, including OS and biomarker analyses by EGFR status.
Conclusion: Combining intercalated erlotinib with chemotherapy as a first-line 
treatment strategy can significantly prolong PFS in Chinese patients with advanced 
NSCLC, with similar results to the overall study population.
Keywords: chemotherapy, first line, Erlotinib, NSCLC
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O-036: MIR-214 REGULATES EPITHELIAL-TO-MESENCHYMAL 
TRANSITION AND IS ASSOCIATED WITH RESISTANCE TO GEFI-
TINIB IN AN EGFR-MUTANT CELL LINE
Yongsheng Wang1, Hongping Xia2, Shengxiang Ren3, Caicun Zhou4, L Miao1  
1Nanjing Gulou Hospital, Nanjing/CHINA, 2Division Of Cellular And Molecular 
Research, National Cancer Center, /SINGAPORE, 3Shanghai Pulmonary Hospital/
CHINA, 4School Of Medicine, Tongji University, Shanghai Pulmonary Hospital, 
Shanghai/CHINA
Background: Although patients with non-small cell lung cancer (NSCLC) who have an 
activating EGFR mutation receive a clinical benefit from EGFR tyrosine kinase inhibitors 
(TKIs), namely gefitinib and erlotinib, these patients eventually develop resistance to 
EGFR-TKIs. Resistance may result from EGFR gene secondary mutations, such as 
T790M, or MET gene amplification. However, other mechanisms urgently need to be 
explored. MicroRNAs are a class of small non-coding RNAs that play pivotal roles in 
tumorigenesis, tumor progression and chemoresistance. In this study, we investigated 
whether miRNA (miR-214) regulates resistance to EGFR-TKIs in NSCLC. Methods: The 
geftinib-resistant cell line HCC827/GR was established by exposure to increasing 
concentrations of gefitinib. Morphological changes were observed by light microscopy 
and epithelial-to-mesenchymal transition (EMT) markers were detected by western blot. 
Cell viability was evaluated by MTS assays. The migration and invasion capacity of cells 
were analyzed by wound healing and in vitro Matrigel invasion assays. The expression of 
miR-214 and its downstream target PTEN were analyzed by real-time quantitative 
RT-PCR, northern blot or western blot. Furthermore, the expression of miR-214 in 
HCC827/GR cells was suppressed by a P-miRZip-214 construct. EMT-related markers 
and components of the PI3K/AKT pathway were analyzed by western blot. Results: The 
established HCC827/GR cells showed markers of EMT and their migration/invasion 
capacity was enhanced compared with HCC827. Interestingly, miR-214 was significantly 
upregulated in HCC827/GR. Furthermore, knockdown of miR-214 resulted in 
mesenchymal-to-epithelial transition and the loss of migration/invasive capacity in 
HCC827/GR. miR-214 knockdown also sensitized HCC827/GR to gefitinib and altered 
the expression of PTEN and p-AKT.
 
Conclusion: Up-regulation of miR-214 and PTEN inactivation is associated with 
HCC827 cell resistance to gefitinib by regulating EMT. Therapeutic strategies to suppress 
miR-214 expression or activate PTEN may reverse resistance to EGFR-TKI therapy in the 
future.
Keywords: miR-214, PTEN, EMT, gefitinib
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O-037: THE COMBINATION OF FIVE CHANGES (TELOMERASE, 
P16/RB BYPASS, P53 KNOCKDOWN, KRASV12, C-MYC) TO-
GETHER WITH SERUM-INDUCED EPITHELIAL MESENCHYMAL 
TRANSITION PROGRESSES NORMAL HUMAN BRONCHIAL 
EPITHELIAL CELLS TO FULL MALIGNANCY
Mitsuo Sato1, Jill E. Larsen2, Woochang Lee2, David Shames3, Ignacio I. Wistuba4, Adi F. 
Gazdar3, Jerry W. Shay5, John D. Minna3, Masashi Kondo1, Yoshinori Hasegawa1  
1Department Of Respiratory Medicine, Nagoya University Graduate School Of Medicine, 
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Background: To study the importance of various mutations being found in current 
genome-wide sequencing efforts, we have developed a model human lung epithelial cell 
system (cdk4/hTERT-immortalized normal human bronchial epithelial cells (HBECs)). 
We previously showed that the combination of p53 knockdown (KD) and KRASV12 or 
mutant EGFR led HBECs to form soft agar colonies but failed to cause the cells to form 
xenograft tumor (Sato et al. Cancer Res 2006). Methods: To progress the HBECs to full 
malignancy, we explored three additional steps: 1) high levels of KRASV12, 2) introducing 
c-Myc, and 3) switching culture medium from serum-free to serum containing medium. 
Microarray analysis of tumorigenic and non-tumorigenic HBEC clones was done to 
identify gene expression signature that could predict prognosis of lung cancer patients. 
Results: High levels of KRASV12 induced senescence in HBECs, which was partially 
alleviated by p53 KD. When combined with p53 KD, HBECs with high levels of KRASV12 
(designated HBEC3RL53) formed a subset of very large soft agar colonies, and formed 
xenograft tumors (3 tumors/ 9 mice). Introducing c-Myc into HBEC3RL53 (designated 
HBEC3RL53M) dramatically increased the number of soft agar colonies, but did not 
enhance tumorigenicity (3 tumors /10 mice). Switching culture medium from serum-
free to serum-containing medium caused HBEC3RL53M cells to lose their epithelial 
phenotype and progressed the HBEC3RL53Ms to frank malignancy (7 tumors/7 mice). 
Notably, these manipulated HBECs produced divergent subtypes seen in naturally 
occurring lung cancer: adenocarcinoma, adenosquamous carcinoma, squamous cell 
carcinoma, and poorly differentiated carcinomas with typical morphologic features 
of each histology. Genome-wide analysis of tumorigenic and non-tumorigenic clones 
identified an mRNA signature that could predict outcome as well as tumor histology in 
patients with lung cancer. Conclusion: These results demonstrate that a minimum of 
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five changes (telomerase, p16/Rb bypass, p53 KD, mutant KRASV12, c-Myc) and serum-
induced EMT are required to progresses normal human bronchial epithelial cells to full 
malignancy and that the HBEC model has the great capability of developing and testing 
lung cancer therapeutics.
Keywords: EMT, multistep carcinogenesis, LUNG CANCER
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O-038: BRAF MUTATIONS IN PATIENTS WITH NON-SMALL CELL 
LUNG CANCER: A POOLED ANALYSIS
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Background: BRAF mutations have been found to be a driver mutation and maybe 
a therapy target in patients with non-small cell lung cancer (NSCLC). We sought 
to compile the available researches of BRAF mutations to better understand the 
characteristic of BRAF mutant patients with NSCLC. Methods: We searched published 
researches involving BRAF mutations and NSCLC. 15 reports were identified (published 
between June 2002 and Sep 2011). We used direct data as extracted from the author’s 
publication for BRAF mutation frequency and other clinicopathologic analysis. 
Results: Over 4,100 NSCLCs-comprising 3,383 adenocarcinomas (ADCs) and 842 lung 
squamous cell carcinomas (SCCs)-were pooled from these studies. The frequency of 
BRAF mutations is approximately 2.7% (93/3383) in ADCs, and 0.7% in others (p<0.001). 
BRAF mutations (including both V600E mutations and non-V600E) were high frequently 
associated with smoking history (38 of 57 patients and 32 of the 35 patients; 66.7% and 
91.4%, respectively, p=0.007). In lung ADCs subgroup V600E mutations were frequent 
in female (40 of 56 patients; 71.4%) while non-V600E mutations were prevalent in 
males (22of 35 patients; 62.9%), as indicated by Pearson Chi-square analysis (p=0.001). 
However, the majority of patients harboring BRAF mutations in SCCs are non-V600E, 
male, and former or current smokers; leaving only one SCC (16.7%) with V600E mutant. 
Conclusion: We conducted the largest survey of BRAF mutations in patients with 
NSCLC to date. BRAF mutations were associated with the gender and smoking history of 
patients with NSCLC. This characteristics of BRAF mutations may facilitate in selecting 
patients for therapy targeted BRAF in the future.
Keywords: BRAF mutation, clinical feature, NSCLC
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O-039: NESTED CASE CONTROL STUDY OF PROTEOMIC BIO-
MARKERS FOR INTERSTITIAL LUNG DISEASE IN JAPANESE 
PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED 
WITH ERLOTINIB
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Background: Interstitial lung disease (ILD) is a serious adverse drug reaction associated 
with EGFR tyrosine kinase inhibitors, but its risk factors are yet to be elucidated. We 
sought to identify the proteomic biomarkers associated with ILD in Japanese patients 
with non-small cell lung cancer treated with erlotinib, and to build predictive models 
for development of ILD using the proteomic biomarkers. Methods: We conducted a 
nested case control study. The cases were subjects in whom ILD developed within 120 
days after the administration of erlotinib following enrolment in the cohort, and the 
controls were randomly selected from patients without ILD who were treated with 
erlotinib. For the proteomics analysis, albumin and IgG were removed from serum 
samples obtained before the first administration of erlotinib, then the samples were 
digested with protease and the resultant peptide fragments were separated, identified 
and assayed by LC–MS/MS. Logistic regression analysis was used for the identification 
and examination of predictability for ILD. Results: A total of 645 patients were enrolled 
in the cohort, 15 cases and 64 controls were analysed. Logistic regression analysis was 
performed to identify the peptide peaks and proteins assossiated with ILD. When 
multiplicity was taken into account, we were unable to statistically verify any genuine 
association between individual markers and ILD. Investigation of the predictive power 
based on leave-one-out cross-validation showed that the area under the ROC curve was 
0.73 at a maximum. However, additional analysis suggested that three proteins (C3, 
C4A/C4B and APOA1) have a stronger association with ILD than the other proteins 
tested. Conclusion: We were unable to conclude from the results of this study that any 
promising serum protein markers for predicting ILD had been identified. However, C3, 
C4A/C4B and APOA1 were suggested to be worth further investigation.
Keywords: Interstitial Lung Disease, Erlotinib, non-small cell lung cancer, Proteomic 
Biomaker
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O-040: SUBSET ANALYSES OF EAST ASIAN PATIENTS ENROLLED 
IN THE MISSION PHASE III, RANDOMIZED, DOUBLE-BLIND, 
PLACEBO-CONTROLLED TRIAL OF SORAFENIB MONOTHER-
APY IN PATIENTS WITH ADVANCED RELAPSED/REFRACTORY 
NSCLC OF PREDOMINANTLY NON-SQUAMOUS HISTOLOGY 
WHO FAILED 2–3 CHEMOTHERAPY REGIMENS
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Background: Sorafenib monotherapy showed activity in a randomized phase II trial 
of patients with advanced NSCLC who failed 2–3 chemotherapy regimens. The Phase 
III MISSION trial assessed whether third- or fourth-line treatment with sorafenib plus 
best supportive care (BSC) would improve overall survival (OS), relative to BSC alone, 
in patients with advanced relapsed/refractory NSCLC of predominantly non-squamous 
histology. Methods: Eligible patients were randomized 1:1 to oral sorafenib 400 mg bid 
or matching placebo on a continuous basis until disease progression, intolerable toxicity 
or withdrawal of consent. Patients were stratified by geographic region, number of prior 
lines of treatment, brain metastases, and prior treatment with an EGFR inhibitor. The 
primary endpoint was OS in the intent-to-treat (ITT) population; secondary endpoints 
included progression free survival (PFS), time to progression (TTP), disease control 
rate (DCR), and safety. Results: Overall, 703 patients were randomized, 353 to placebo 
and 350 to sorafenib. Median OS was similar in the two groups, whereas median PFS 
and TTP were greater in the sorafenib group (Table). The East Asian subgroup included 
304 patients from China, Japan, Korea, Taiwan, and Hong Kong. Baseline demographic 
factors were generally balanced between treatment groups, with only minor imbalances 
in (sorafenib vs placebo) female gender (51% vs 41%), non-smokers (63% vs 55%) and 
adenocarcinoma histology (84% vs 88%). Analysis of baseline EGFR mutations in 
DNA isolated from plasma and/or tumor samples from approximately half the patients 
indicated that the frequency of EGFR mutations was higher in East Asian patients (43%) 
than in the overall study population (26%), with no imbalance between the sorafenib and 
placebo groups. Median OS, PFS and TTP were longer in East Asian patients randomized 
to sorafenib than to placebo. Data on adverse events, drug dose intensity, pre- and post-
trial treatments and subpopulations will be presented Table. Efficacy Results for ITT 
Populations 
Overall Population (n=703) 
Assessment Placebo (n=353) 
Sorafenib 
(n=350) HR (95% CI) 
Median OS, days 253 248 0.99 (0.84-1.17) 
Median PFS, days 43 84 0.61 (0.51-0.72) 
Median TTP, days 43 89 0.54 (0.45-0.65) 
EGFR mutation, n (%) 45/181 (25) 44/166 (27) 
East Asian Population (n=304) 
Assessment Placebo (n=152) 
Sorafenib 
(n=152) HR (95% CI) 
Median OS, days 271 296 0.84 (0.66-1.08) 
Median PFS, days 42 84 0.46 (0.36-0.59) 
Median TTP, days 42 84 0.44 (0.34-0.57) 
EGFR mutation, n (%) 32/74 (43) 30/70 (43) 
 
Conclusion: Analysis of the East Asian patient cohort showed better sorafenib-
associated outcomes than in the overall population. The activity of third/fourth line 
sorafenib monotherapy in East Asian patients with advanced relapsed/refractory 
NSCLC of predominantly non-squamous histology is consistent with its activity as first 
line treatment, together with gemcitabine and cisplatin, in the NExUS trial (APLCC 
2010). Better outcomes with sorafenib in East Asian populations may be related to 
the higher incidence of EGFR mutations in this subgroup. This study was supported 
by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals. NCT-00863746, 
EudraCT-2008-006914-62.
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